The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours: A non-cisplatin-based regimen.
Waleed Badreldin
No relevant relationships to disclose
Simon Chowdhury
No relevant relationships to disclose
Stephen John Harland
Honoraria - Sanofi
Danish Mazhar
No relevant relationships to disclose
Thomas Powles
No relevant relationships to disclose
Peter Wilson
No relevant relationships to disclose
Jonathan Shamash
No relevant relationships to disclose